Journal
GEROSCIENCE
Volume 43, Issue 2, Pages 463-485Publisher
SPRINGER
DOI: 10.1007/s11357-021-00358-6
Keywords
Epigenetics; Aging; Reprogramming; Rejuvenation
Categories
Funding
- EPSRC Centre for Doctoral Training in Synthesis for Biology and Medicine [EP/L015838/1]
- AstraZeneca
- Diamond Light Source
- Defence Science and Technology Laboratory
- Evotec
- GlaxoSmithKline
- Janssen
- Novartis
- Pfizer
- Syngenta
- Takeda
- UCB
- Vertex
Ask authors/readers for more resources
This review explores the interplay between epigenetics and aging, with a focus on the potential of epigenetic reprogramming for age reversal. While in vivo partial reprogramming holds promise as a therapy, there are several limitations that need to be addressed. Reprogramming for rejuvenation is a young but rapidly expanding subfield in the biology of aging.
Aging has become one of the fastest-growing research topics in biology. However, exactly how the aging process occurs remains unknown. Epigenetics plays a significant role, and several epigenetic interventions can modulate lifespan. This review will explore the interplay between epigenetics and aging, and how epigenetic reprogramming can be harnessed for age reversal. In vivo partial reprogramming holds great promise as a possible therapy, but several limitations remain. Rejuvenation by reprogramming is a young but rapidly expanding subfield in the biology of aging.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available